...
首页> 外文期刊>Heart >Effects of β receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol
【24h】

Effects of β receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol

机译:β受体拮抗剂的患者的影响心力衰竭的临床证据心肌梗死:双盲比较美托洛尔和xamoterol

获取原文
获取原文并翻译 | 示例
           

摘要

Objective-To evaluate whether xamoterol, a partial agonist, would improve exercise time more than metoprolol in patients with mild to moderate heart failure after a myocardial infarction. Design-Single-centre double blind randomised parallel group comparison of metoprolol 50-100 mg and xamoterol 100-200 mg twice daily. Patients-210 patients aged 40-80 years (173 men) with clinical evidence of heart failure early after a myocardial infarction. 106 were given metoprolol and 104 xamoterol. Main outcome measures-Exercise test results and performance at three months; the exercise test, quality of life, and clinical assessments at baseline (5-7 days after the infarction) and after 3, 6, and 12 months. Results-Exercise time increased at three months by 22% in the metoprolol group and 29% in the xamoterol group, but with no significant difference between the groups. Patients taking xamoterol showed overall non-significantly higher mean values of exercise time achieved with higher heart rates at rest and exercise. Improvements in quality of life, clinical signs of heart failure, and New York Heart Association functional class were seen in both treatment groups over one year, with minor benefits of xamoterol on breathlessness, peripheral oedema, and functional class. Eighteen patients taking metoprolol and 22 taking xamoterol withdrew from the study during one year, with a low mortality, rein-farction rate, and progress of heart failure in both treatment groups. Mean dose from baseline to 3 months was 135 mg metoprolol and 347 mg xamoterol. Conclusion-β_1 Receptor antagonists with or without partial agonist activity are safe to use in mild to moderate heart failure after a myocardial infarction. Exercise tolerance, quality of life, and clinical signs and functional class of heart failure improve, and few patients show deterioration in their condition. Exercise tolerance is no better with xamoterol than metoprolol.
机译::靠评估是否xamoterol,部分受体激动剂,可以改善运动时间超过美托洛尔在轻度至中度患者心肌梗死后心力衰竭。Design-Single-centre双盲随机平行组比较美托洛尔50 - 100毫克和xamoterol 100 - 200毫克每日两次。病人- 40 - 80岁的210名患者(173人)早期心力衰竭的临床证据心肌梗死后。美托洛尔和104 xamoterol。measures-Exercise测试结果和性能三个月;在基线和临床评估(5 - 7天梗死后)和后3、6和12个月。个月美托洛尔组的22%和29%xamoterol组,但无显著群体之间的差异。xamoterol显示总体不高取得了较高的平均值的锻炼时间心率在休息和锻炼。生活质量,临床心力衰竭的迹象,和纽约心脏协会功能类在一年之内出现在两个治疗组,与小xamoterol的好处呼吸困难、周围水肿和功能类。采取xamoterol退出研究期间一年,与低死亡率,rein-farction率和心脏衰竭的进展治疗组。个月135毫克美托洛尔和347毫克xamoterol。有或没有部分激动剂活动是安全的用在轻度至中度心衰心肌梗塞。生活质量,临床症状功能类心衰改善,一些患者显示恶化条件。比美托洛尔xamoterol。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号